Allergy Therapeutics (LON:AGY) Hits New 1-Year High – Still a Buy?

Allergy Therapeutics plc (LON:AGY) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as GBX 12.10 and last traded at GBX 12.10, with a volume of 469480 shares traded. The stock had previously closed at GBX 11.70.

Allergy Therapeutics Stock Down 2.6%

The company has a debt-to-equity ratio of 835.48, a quick ratio of 1.48 and a current ratio of 1.63. The firm’s 50 day moving average price is GBX 11.26 and its two-hundred day moving average price is GBX 9.63. The company has a market cap of £717.87 million, a P/E ratio of -13.92, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.

Allergy Therapeutics (LON:AGY) last issued its earnings results on Monday, February 16th. The company reported GBX (0.84) earnings per share for the quarter. Allergy Therapeutics had a negative return on equity of 266.59% and a negative net margin of 72.86%. Equities research analysts anticipate that Allergy Therapeutics plc will post -2.56 EPS for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.